253 related articles for article (PubMed ID: 23791371)
1. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.
Zhang ZH; Liu HY; Hernandez-Da Mota SE; Romano MR; Falavarjani KG; Ahmadieh H; Xu X; Liu K
Am J Ophthalmol; 2013 Jul; 156(1):106-115.e2. PubMed ID: 23791371
[TBL] [Abstract][Full Text] [Related]
2. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
5. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.
Ahn J; Woo SJ; Chung H; Park KH
Ophthalmology; 2011 Nov; 118(11):2218-26. PubMed ID: 21724263
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.
Zhao XY; Xia S; Chen YX
Br J Ophthalmol; 2018 Aug; 102(8):1077-1085. PubMed ID: 29246890
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.
Yeh PT; Yang CM; Lin YC; Chen MS; Yang CH
Retina; 2009 Jun; 29(6):768-74. PubMed ID: 19516117
[TBL] [Abstract][Full Text] [Related]
9. Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage.
Farahvash MS; Majidi AR; Roohipoor R; Ghassemi F
Retina; 2011; 31(7):1254-60. PubMed ID: 21499192
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
[TBL] [Abstract][Full Text] [Related]
11. The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage.
Berk Ergun S; Toklu Y; Cakmak HB; Raza S; Simsek S
Semin Ophthalmol; 2015 May; 30(3):177-80. PubMed ID: 24409948
[TBL] [Abstract][Full Text] [Related]
12. RANDOMIZED CONTROLLED STUDY OF INTRAVITREAL BEVACIZUMAB 0.16 MG INJECTED ONE DAY BEFORE SURGERY FOR PROLIFERATIVE DIABETIC RETINOPATHY.
Manabe A; Shimada H; Hattori T; Nakashizuka H; Yuzawa M
Retina; 2015 Sep; 35(9):1800-7. PubMed ID: 25932549
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy.
Yang CM; Yeh PT; Yang CH; Chen MS
Am J Ophthalmol; 2008 Aug; 146(2):211-217. PubMed ID: 18547539
[TBL] [Abstract][Full Text] [Related]
14. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.
Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY
Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001
[TBL] [Abstract][Full Text] [Related]
15. Early vitreous hemorrhage after vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
Sato T; Morita S; Bando H; Sato S; Ikeda T; Emi K
Middle East Afr J Ophthalmol; 2013; 20(1):51-5. PubMed ID: 23580852
[TBL] [Abstract][Full Text] [Related]
16. Influence of preoperative intravitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy.
Ushida H; Kachi S; Asami T; Ishikawa K; Kondo M; Terasaki H
Ophthalmic Res; 2013; 49(1):30-6. PubMed ID: 23038607
[TBL] [Abstract][Full Text] [Related]
17. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment.
Yeung L; Liu L; Wu WC; Kuo YH; Chao AN; Chen KJ; Yang KJ; Chen TL; Lai CC
Acta Ophthalmol; 2010 Sep; 88(6):635-40. PubMed ID: 19432872
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review and Meta-Analysis of Clinical Outcomes of Small Gauge Vitrectomy with or without Intravitreal Anti-Vascular Endothelial Growth Factor Agents Pretreatment for Proliferative Diabetic Retinopathy.
Pei M; Zhao X; Wan G
Ophthalmic Res; 2023; 66(1):777-790. PubMed ID: 36972566
[TBL] [Abstract][Full Text] [Related]
19. [Use of bevacizumab in the treatment of complicated proliferative diabetic retinopathy].
Benhmidoune L; McHachi A; Boukhrissa M; Chakib A; Rachid R; Elbelhadji M; Amraoui A
J Fr Ophtalmol; 2013 Nov; 36(9):758-63. PubMed ID: 23830522
[TBL] [Abstract][Full Text] [Related]
20. Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab.
Hu X; Pan Q; Zheng J; Song Z; Zhang Z
BMC Ophthalmol; 2019 Sep; 19(1):200. PubMed ID: 31519158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
